GlobalData on MSN17h
GSK gains approval in Japan for extended indication of RSV vaccine
GSK has received approval from Japan's MHLW for its application to extend the indication of its RSV vaccine, Arexvy.
GSK announces Japan’s MHLW approved application to extend indication of Arexvy
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include ...
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...
TOP NEWS: GSK's Arexvy RSV vaccine approved in Japan for adults 50-59
(Alliance News) - GSK PLC said on Friday that Japan's Ministry of Health, Labour & Welfare has approved the expansion of its Arexvy respiratory syncytial virus vaccine to include adults aged 50 to 59 ...
London South East4d
GSK's Arexvy approved for wider age range in Japan
(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider ...
FiercePharma1d
Pfizer led industrywide sales surge in Q3 after several quarters of dominance by Eli Lilly, Novo Nordisk
After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...
Pharmabiz2d
Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...
FiercePharma26d
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...
Business Insider4d
GSK Plc Announces Regulatory Expansion For Arexvy In Japan To Include Adults Aged 50-59
(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV ...